Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate : a chart review of Spanish adults with attention-deficit hyperactivity disorder.
about
European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHDLong-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challengesAdherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder - a systematic literature reviewUpdate on the management of attention-deficit/hyperactivity disorder in children and adults: patient considerations and the role of lisdexamfetamine.Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment optionsTreatments for Adolescents With Comorbid ADHD and Substance Use Disorder: A Systematic Review.Once-daily medications for the pharmacological management of ADHD in adultsSafety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.Behavioral, neurocognitive and treatment overlap between attention-deficit/hyperactivity disorder and mood instability.OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder.Toward quality care in ADHD: defining the goals of treatment.Attention-deficit/hyperactivity disorder: an update on medication adherence and persistence in children, adolescents and adults.A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.Adult ADHD: A new disease?Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers.Description of study population and analysis of factors influencing adherence in the observational Italian study "Evaluation of Pharmacotherapy Adherence in Bipolar Disorder" (EPHAR).Opportunities to reduce medication regimen complexity: a retrospective analysis of patients discharged from a university hospital in Germany.Meta-analysis of brain-derived neurotrophic factor p.Val66Met in adult ADHD in four European populations.Medication use in adults with attention deficit/hyperactivity disorder in a commercially-insured population in the United States.Triple-Bead Mixed Amphetamine Salts (SHP465) in Adults With ADHD: Results of a Phase 3, Double-Blind, Randomized, Forced-Dose Trial.Beyond the pill: new medication delivery options for ADHD.A clinician's guide to ADHD treatment options.Social adjustment and family function after drug switch from IR -methylphenidate to OROS-methylphenidate in patients with attention-deficit/hyperactivity disorder
P2860
Q21260332-1ABBF001-B859-4E03-8DEA-F562A0770B27Q26822392-C9347524-D820-4045-B71F-A17C3DCA5E08Q26859455-72287BD3-264F-438F-9013-ECE17D7E9425Q33571016-34FFE24F-A370-463E-90E8-921A40965B9EQ34286130-C2B68A5A-FAEE-4321-9738-EC89FCA852A5Q36338808-79A2D313-AB5D-4C99-BFCA-7A84C0ED16F3Q37230351-8FB0A934-868B-4171-9E64-312084858D9EQ37354631-CDA22FDF-BF32-4A2B-A225-AC7166F883EDQ37432189-4427536E-FB00-4A19-A9FA-51CCECB2C810Q37578475-ACECBB0B-12A9-46BF-8A85-E2E7A3E42A32Q37827879-E2F1B001-2B20-479C-9FFA-24584D3185ABQ38082894-F2E1F2CA-68BD-4345-8F62-073146CD2140Q38161921-89511DB6-AA47-43FD-8BD9-AE94757E5A2EQ38239633-75ED981A-8E7E-44D2-8345-D5BDACA2E768Q38799949-6EE5E568-D380-47BA-BDA2-E3944133615DQ43155088-08A7F5CB-95B5-4658-B139-6B84C50564FCQ44594822-0EFFFDEE-A298-4538-B60A-5DA41784E994Q45375703-29515F1C-5890-4A49-83FA-862F83B9744DQ45928941-599D33DD-A318-45EC-A3D3-424A8F49ABD7Q47571549-10D25E19-A039-47EA-83A5-BB620A8048C1Q47741544-53D637BC-4CD3-4701-971F-31A40FAA535AQ50433156-EC88B3BB-B4D4-415F-A1BF-D40853073E91Q53132267-51BD3E68-C8E8-4DF6-AD20-2C5CB4F3742DQ58698663-E1612ED8-A3D3-42DE-89F9-379C1950FCAC
P2860
Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate : a chart review of Spanish adults with attention-deficit hyperactivity disorder.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effect of switching drug formu ...... eficit hyperactivity disorder.
@en
Effect of switching drug formu ...... eficit hyperactivity disorder.
@nl
type
label
Effect of switching drug formu ...... eficit hyperactivity disorder.
@en
Effect of switching drug formu ...... eficit hyperactivity disorder.
@nl
prefLabel
Effect of switching drug formu ...... eficit hyperactivity disorder.
@en
Effect of switching drug formu ...... eficit hyperactivity disorder.
@nl
P2093
P1433
P1476
Effect of switching drug formu ...... eficit hyperactivity disorder.
@en
P2093
Marc Ferrer
Mariana Nogueira
Miguel Casas
Nuria Gómez
Sergi Valero
Silvia Yelmo
Xavier Castells
Yolanda Martínez
P304
P356
10.2165/00023210-200822070-00005
P577
2008-01-01T00:00:00Z
P6179
1007387499